Epigenetics: EpiSwitch 3D-Genomic Diagnostic - Replication, Cross-Condition Specificity, and Competing Evidence

Scope: Literature surrounding the EpiSwitch 3D-genomic blood test for ME/CFS (Hunter 2025). Covers: (1) the EpiSwitch platform’s prior-art and cross-disease clinical use; (2) independent mechanistic evidence that 3D chromatin topology regulates the IL-2/JAK-STAT axis the test reports; (3) competing blood epigenetic biomarkers (HERV, OPRM1 methylation, lncRNA) that partially overlap the EpiSwitch claims; (4) null/replication-gap findings. Hunter 2025 itself is annotated in the Immune Dysfunction section.

1 Peppercorn et al. 2025 — DNA Methylation Landscapes in ME/CFS vs Long COVID PBMCs

(Peppercorn et al. 2025)

Full Citation:: Peppercorn K, Sharma S, Edgar CD, Stockwell PA, Rodger EJ, Chatterjee A, Tate WP. “Comparing DNA Methylation Landscapes in Peripheral Blood from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Patients.” International Journal of Molecular Sciences. 2025;26(14):6631. DOI:: 10.3390/ijms26146631 PMID:: 40724879 PMCID:: PMC12294161 Published:: July 10, 2025 Study Design:: Comparative cross-sectional RRBS (reduced representation bisulphite sequencing) of PBMC DNA from age/sex-matched cohorts: n=5 ME/CFS, n=5 Long COVID (LC), n=5 healthy controls. University of Otago. Key Findings::

- ME/CFS: 214 differentially methylated fragments (DMFs) vs HC (>10 % methylation difference, p < 0.05); 145 hypermethylated, 69 hypomethylated (67.8 % hypermethylation dominant).
- Long COVID: 429 DMFs vs HC (281 hypermethylated, 148 hypomethylated) — LC shows more abundant methylation changes than ME/CFS.
- 118 DMFs common to both cohorts (Pearson R = 0.88), indicating a largely shared epigenetic makeup; 26 of 118 show >10 % methylation difference between the two disease cohorts and 6 show opposite-direction changes.
- PCA separates ME/CFS, LC, and HC into three distinct clusters; global methylomes otherwise similar across chromosomes except sex chromosomes.
- Promoter/exon DMFs mainly hypermethylated; 12 promoter and 6 exon DMFs linked to genes (e.g., LGALS3, CHD7, STAT5A, ABCA7) relevant to immune and metabolic function.
- 6 of 26 divergent DMFs show opposite-direction methylation between LC and ME/CFS (five hypermethylated in LC but hypomethylated in ME/CFS; one the reverse) — potential disease-specific signatures.

Conclusion:: Documents a generally shared epigenetic makeup between ME/CFS and Long COVID with specific, distinct methylation changes. Differences likely reflect disease stage (LC ~1 year vs ME/CFS ~12 years from onset) or SARS-CoV-2-specific effects. Establishes the comparative methylome as a foundation for larger, stage-matched studies. Limitations:: Very small n (5 per cohort); single lab (Otago, no independent replication); cross-sectional (no directionality); PBMC proxy, not tissue/brain; functional significance of DMFs not experimentally validated; stage mismatch (LC 1 yr vs ME/CFS 12 yr) confounds disease-specific vs time-from-onset attribution. Certainty:: 0.52

2 Stabile et al. 2024 — miR-153-3p Elevation Causes Short-Term Memory Deficits in Mice

(Stabile et al. 2024)

Full Citation:: Stabile F, Torromino G, Rajendran S, Del Vecchio G, Presutti C, Mannironi C, De Leonibus E, Mele A, Rinaldi A. “Short-Term Memory Deficit Associates with miR-153-3p Upregulation in the Hippocampus of Middle-Aged Mice.” Molecular Neurobiology. 2024;61(5):3031–3041. DOI:: 10.1007/s12035-023-03770-5 PMID:: 37964090 Study Design:: Mouse model; 6-DOT behavioral task; n=29 middle-aged (12-month) CD1 male mice + 25 adult mice for intra-hippocampal mimic injection; microarray miRNA profiling + RT-qPCR. Key Findings::

- miR-153-3p upregulated in hippocampus of cognitively impaired mice
- Intra-hippocampal injection of miR-153-3p mimic in adult mice sufficient to induce short-term memory deficit
- Proposed as biomarker for early cognitive decline linked to synaptic plasticity dysregulation

Conclusion:: Causal evidence (in mice) that elevated miR-153-3p impairs short-term memory. Mechanistically relevant to ME/CFS brain fog: in ME/CFS the finding is reduced miR-153-3p (Chalder 2026), which is a different direction — this study concerns overexpression, not reduction. The relationship between miR-153-3p levels and memory appears non-linear. Limitations:: Rodent model only; male mice only; functional targets not fully elucidated; direction of effect (over- vs under-expression) requires reconciliation with ME/CFS data. Certainty:: 0.48

3 Lahiri et al. 2025 — miR-153-3p as Protective Biomarker in Alzheimer’s Disease

(Lahiri et al. 2025)

Full Citation:: Lahiri DK, Wang R, Maloney B, Ghetti B, Nho K, Farlow MR, Saykin AJ, White FA, Sambamurti K, Counts SE. “Evidence of miR-153-3p association with Alzheimer’s disease (AD) and the mechanism of miR-153-3p on critical proteins suggest a therapeutic and biomarker potential of miR-153-3p in AD and related dementias.” Alzheimer’s & Dementia. 2025;21(Suppl 8):e110012. DOI:: 10.1002/alz70862_110012 Study Design:: Human brain tissue qRT-PCR; SNP association with nine AD endophenotypes; RNA-seq pathway analysis. Key Findings::

- Elevation of miR-153-3p associated with REDUCED probability of Alzheimer's disease (neuroprotective)
- miR-153-3p reduces expression of APP, SNCA (alpha-synuclein), and REST
- Axonal guidance pathway involvement

Conclusion:: At normal/elevated levels miR-153-3p is neuroprotective — reducing amyloidogenic (APP) and aggregation-prone (SNCA) proteins. This is consistent with reduced miR-153-3p in ME/CFS (Chalder 2026) contributing to cognitive dysfunction via loss of this neuroprotective activity. Limitations:: Conference abstract; limited methodological detail; post-hoc association study; directionality of effect in ME/CFS vs AD contexts differs. Certainty:: 0.40

4 Li et al. 2022 — miR-153-3p Neuroprotective in Ischemia/Reperfusion Stroke Model

(Li et al. 2022)

Full Citation:: Li Y, Peng B, Li Y, Huang A, Peng Y, Yu Q, Li Y. “MiR-203a-3p/153-3p improves cognitive impairments induced by ischemia/reperfusion via blockade of SRC-mediated MAPK signaling pathway in ischemic stroke.” Chemico-Biological Interactions. 2022;358:109900. DOI:: 10.1016/j.cbi.2022.109900 PMID:: 35305977 Study Design:: In vitro / animal ischemia/reperfusion model. Key Findings::

- miR-153-3p downregulated following ischemia/reperfusion injury
- Direct inhibitor of SRC protein; reduces neuronal apoptosis and NLRP3 inflammasome activity via MAPK pathway
- Restoration of miR-153-3p improves cognitive deficits

Conclusion:: Confirms neuroprotective role of miR-153-3p when present at normal/elevated levels. Reduced miR-153-3p → cognitive impairment: consistent with Chalder 2026 (lower miR-153-3p correlates with worse delayed memory in ME/CFS). Limitations:: Animal/cell model; clinical translation unclear. Certainty:: 0.42

5 Stojilkovic et al. 2025 — PTPRN2 Biology Review: Neuroendocrine Roles

(Stojilkovic, Sokanovic, and Constantin 2025)

Full Citation:: Stojilkovic SS, Sokanovic SJ, Constantin S. “What is known and unknown about the role of neuroendocrine genes Ptprn and Ptprn2.” Frontiers in Endocrinology. 2025;16:1531723. DOI:: 10.3389/fendo.2025.1531723 PMID:: 39926347 Study Design:: Comprehensive narrative review. Key Findings::

- PTPRN2 (IA-2beta/phogrin) is a pseudophosphatase expressed in hypothalamus, pituitary, hippocampus, pancreatic islets, and neurons broadly
- Required for normal accumulation of neurotransmitters norepinephrine, dopamine, and serotonin in the brain
- Required for normal secretory vesicle accumulation in hippocampus and pituitary
- Double KO: female-specific impaired ovulation (kisspeptin neuron development); PTPRN2 suppresses POMC/melanotroph proliferation
- Can dephosphorylate PI(3)P and PI(4,5)P2 (phospholipid phosphatase activity)

Conclusion:: Establishes PTPRN2 as a broad neuroendocrine regulator. Hypomethylation of PTPRN2 in ME/CFS (Chalder 2026) would be expected to alter expression or activity in neurons relevant to cognition, monoamine signaling, and autonomic regulation. Limitations:: Review paper; direct evidence linking PTPRN2 function to ME/CFS not yet established. Certainty:: 0.62

6 Choza et al. 2024 — PTPRN2 Epigenetic Dysregulation in Parkinson’s Disease Brain (Preprint)

(Choza et al. 2024)

Full Citation:: Choza JI, Virani M, Kuhn NC, Adams M, Kochmanski J, Bernstein AI. “Parkinson’s disease-associated shifts between DNA methylation and DNA hydroxymethylation in human brain in PD-related genes, including PARK19 (DNAJC6) and PTPRN2 (IA-2beta).” Research Square (Preprint). 2024. DOI:: 10.21203/rs.3.rs-4572401/v1 PMID:: 39070644 Study Design:: Postmortem brain tissue from PD patients vs matched controls; paired 5mC/5hmC analysis. Key Findings::

- PTPRN2 (IA-2) showed disease-associated shifts between DNA methylation and hydroxymethylation in PD brain
- >1,000 sites with significant 5mC/5hmC shifts across 695 genes
- Findings link PTPRN2 epigenetic regulation to idiopathic PD pathogenesis

Conclusion:: Independent evidence that PTPRN2 locus is subject to epigenetic dysregulation in neurological disease, beyond its established role as a diabetes autoantigen. Corroborates plausibility of Chalder 2026 ME/CFS finding. Limitations:: PREPRINT (not peer-reviewed at time of writing); PD context differs substantially from ME/CFS; causality not established. Certainty:: 0.35

7 Qi et al. 2023 — PHB2 Biology and miRNA-Regulatory Roles in Cancer

(Qi et al. 2023)

Full Citation:: Qi A, Lamont L, Liu E, Murray SD, Meng X, Yang S. “Essential Protein PHB2 and Its Regulatory Mechanisms in Cancer.” Cells. 2023;12(8):1211. DOI:: 10.3390/cells12081211 PMID:: 37190120 Study Design:: Narrative review of PHB2 biology across cancer types. Key Findings::

- PHB2 is pleiotropic: inner mitochondrial membrane mitophagy receptor, nuclear HDAC recruiter, plasma membrane signaling partner
- miRNA-relevant: Lnc34a recruits PHB2/DNMT3A/HDAC1 to silence miR-34a promoter via methylation and deacetylation (epigenetic miRNA silencing)
- PHB2 overexpressed in most human cancers but tumor-suppressive in select contexts

Conclusion:: Establishes mechanistic precedent for PHB2 participating in epigenetic silencing of miRNAs. The Lnc34a-PHB2-miRNA pathway supports the plausibility of the Chalder 2026 hypothesis that PHB2 impairs miR-153-3p maturation. However, direct PHB2-miR-153-3p interaction has not been demonstrated. Limitations:: Review; data primarily from cancer contexts; no ME/CFS or neurological data; direct PHB2-miR-153-3p link not established. Certainty:: 0.58

8 Helliwell et al. 2020 — ME/CFS DNA Methylation Reflects Systemic Dysfunction (RRBS)

(Helliwell et al. 2020)

Full Citation:: Helliwell AM, Sweetman EC, Stockwell PA, Edgar CD, Chatterjee A, Tate WP. “Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions.” Clinical Epigenetics. 2020;12:167. DOI:: 10.1186/s13148-020-00960-z PMID:: 33148325 Study Design:: RRBS on PBMCs; n=10 ME/CFS, 10 age/sex-matched healthy controls. Key Findings::

- 76 differentially methylated fragments; 394 individual differentially methylated cytosines
- Regulatory regions for 17 protein-encoding genes (metabolic/immune)
- 59% of identified genes overlap with prior ME/CFS methylation studies (cross-study convergence signal)
- Enriched pathways: immune, metabolic, and neurological functions

Conclusion:: RRBS-based evidence for systematic DNA methylation dysregulation in ME/CFS PBMCs, with neurological pathway enrichment. Provides independent support for epigenetic involvement in ME/CFS distinct from the saliva-based Chalder 2026 approach. Limitations:: Very small n=10; RRBS covers ~1% of CpG sites; no sex stratification. Certainty:: 0.40

9 Przybylowicz et al. 2023 — DNA Methylation Re-Analysis in Fibromyalgia and CFS

(Przybylowicz et al. 2023)

Full Citation:: Przybylowicz PK, Sokolowska KE, Rola H, Wojdacz TK. “DNA Methylation Changes in Blood Cells of Fibromyalgia and Chronic Fatigue Syndrome Patients.” Journal of Pain Research. 2023;16:4025–4036. DOI:: 10.2147/JPR.S439412 PMID:: 38054109 Study Design:: Re-analysis of three prior CFS/FM methylation datasets (n=127 CFS, n=22 FM) with updated analytical methods. Key Findings::

- Limited site-level overlap across studies but coherent gene-enrichment patterns
- Changes predominantly in regulatory regions (not promoters)
- Clear patient vs control separation across all cohorts

Conclusion:: Methodological inconsistencies across prior studies reduce apparent cross-study reproducibility; with harmonized analysis, convergent pathway-level signals emerge. Suggests regulatory-region methylation is more informative than individual CpG sites. Limitations:: Heterogeneous source datasets; different diagnostic criteria; no sex stratification; re-analysis cannot correct original data quality limitations. Certainty:: 0.45

10 Cheema et al. 2020 — Gender-Specific miRNA Profiling in ME/CFS During Exercise

(Cheema et al. 2020)

Full Citation:: Cheema AK, Sarria L, Bekheit M, Collado F, Almenar-Perez E, Martin-Martinez E, Alegre J, Castro-Marrero J, Fletcher MA, Klimas NG, Oltra E, Nathanson L. “Unravelling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Gender-specific changes in the microRNA expression profiling in ME/CFS.” Journal of Cellular and Molecular Medicine. 2020;24:5865–5877. DOI:: 10.1111/jcmm.15260 PMID:: 32291908 Study Design:: PBMCs; 2-day CPET exercise challenge; n=118 (63 ME/CFS, 55 controls); sex-stratified miRNA profiling. Key Findings::

- Males showed significantly more pronounced miRNA alterations (36 DEGs at peak exercise, FDR\<0.1) vs females (none reaching threshold)
- Consistent elevation of miR-150-5p and miR-423 in ME/CFS across all time-points
- Nutritional state substantially affected miRNA expression

Conclusion:: Sex-differential miRNA response in ME/CFS directly contextualises Chalder 2026 finding of male-specific respiratory symptom association with PTPRN2 hypomethylation. Male-biased epigenetic/miRNA dysregulation in ME/CFS has independent supporting evidence. Limitations:: Exercise challenge context only; miR-153-3p not specifically examined; nutritional confounders present. Certainty:: 0.52

11 Nepotchatykh et al. 2020 — Circulating miRNA Profile in ME/CFS and Symptom Severity

(Nepotchatykh et al. 2020)

Full Citation:: Nepotchatykh E, Elremaly W, Caraus I, Godbout C, Leveau C, Chalder L, et al., Moreau A. “Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology.” Scientific Reports. 2020;10(1):19620. DOI:: 10.1038/s41598-020-76438-y PMID:: 33184353 Study Design:: Circulating miRNA profiling in severely ill ME/CFS patients before/after stress-induced PEM; machine learning clustering (same group as Chalder 2026). Key Findings::

- 11 miRNAs differentially expressed in response to PEM stress challenge
- AUC=1.0 after stress challenge; four symptom-severity clusters identified
- Pathway analysis: immune dysfunction and metabolic dysregulation

Conclusion:: Foundational work by the Moreau group establishing miRNA biomarker strategy and patient subgrouping in ME/CFS that Chalder 2026 extends to DNA methylation. Demonstrates that miRNA profiles correlate with symptom severity clusters. Limitations:: AUC=1.0 raises overfitting concern; sample size not fully reported; PEM-stress context (not resting state). Certainty:: 0.50

12 Nepotchatykh et al. 2023 — miRNA Signatures Discriminate ME/CFS from Fibromyalgia

(Nepotchatykh et al. 2023)

Full Citation:: Nepotchatykh E, Caraus I, Elremaly W, Leveau C, Elbakry M, Godbout C, Rostami-Afshari B, Petre D, Khatami N, Franco A, Moreau A. “Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions.” Scientific Reports. 2023;13(1):1896. DOI:: 10.1038/s41598-023-28955-9 PMID:: 36732593 Study Design:: Circulating miRNA expression + Random Forest classification; ME/CFS vs fibromyalgia vs comorbid conditions (Moreau group). Key Findings::

- 11 miRNAs form expression signature distinguishing ME/CFS from fibromyalgia
- Machine learning model accurately classifies disease groups
- Confirms ME/CFS and fibromyalgia as biologically distinct despite symptom overlap

Conclusion:: Demonstrates that the Moreau group’s miRNA biomarker approach yields disease-specific signatures with diagnostic discriminatory power. Directly precedes Chalder 2026 and represents the miRNA pillar of the dual epigenetic strategy (miRNA expression + DNA methylation). Limitations:: No independent external validation cohort reported; sample size not fully detailed. Certainty:: 0.52

13 Mignolet et al. 2026 — Pathogenic IgG from Long COVID Triggers Pain but Not Cognitive Impairment in Mice

(Mignolet et al. 2026)

Full Citation:: Mignolet M, Deroux C, Florkin T, Bielarz V, De Swert K, Halloin N, Sprimont L, Ladang A, George F, Gilloteaux J, Abeloos L, Garin P, Van Weyenbergh J, Jamoulle M, Diederich C, Gillet NA, Bulpa P, Nicaise C. “Pathogenic IgG from long COVID patients with neurological sequelae triggers sensitive but not cognitive impairments upon transfer into mice.” Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03019-0. DOI:: 10.1007/s00401-026-03019-0 Study Design:: Passive transfer; IgG purified (protein G) from n=13 long COVID patients and n=10 COVID-recovered controls; injected intraperitoneally into mice (n=10 per donor) for 4 consecutive days; behavioral and histological follow-up over 2 weeks. Key Findings::

- LC patient IgG caused transient mechanical hypersensitivity and thermal sensitivity in week 1; effect abolished by IgG depletion or papain digestion (Fc-fragment required)
- No differences in anxiety, depression, or short/long-term spatial memory tests
- No neuroinflammation or astrogliosis detected centrally
- LC IgG accumulated in lumbar dorsal root ganglia, colocalizing with nociceptive and proprioceptive sensory neurons
- LC IgG also bound human post-mortem DRG tissue (ex vivo validation)

Conclusion:: IgG from long COVID patients with neurological sequelae (chronic fatigue, brain fog, pain) is pathogenic via peripheral DRG targeting. Dissociates peripheral pain sensitization from central cognitive mechanisms. Suggests brain fog may not be directly IgG-mediated in the same fashion as pain, or may require longer observation. Limitations:: Small cohort (n=13 LC); transient effect (week 1 only); cognitive tests may have lacked sensitivity or duration; IgG antigens not characterized; IgG subclass data not provided. Certainty:: 0.55

14 Goebel et al. 2021 — Passive Transfer of Fibromyalgia Symptoms from Patients to Mice

(Goebel et al. 2021)

Full Citation:: Goebel A, Krock E, Gentry C, Israel MR, Jurczak A, Morado Urbina C, Sandor K, Vastani N, Maurer M, Cuhadar U, Sensi S, Nomura Y, Menezes J, Baharpoor A, Brieskorn L, Sandström A, Tour J, Kadetoff D, Haglund L, Kosek E, Bevan S, Svensson CI, Andersson DA. “Passive transfer of fibromyalgia symptoms from patients to mice.” Journal of Clinical Investigation. 2021;131(13):e144201. DOI:: 10.1172/JCI144201 PMID:: 34196305 Study Design:: Passive transfer; IgG from n=8 fibromyalgia patients and n=6–12 healthy controls injected into mice; behavioral, electrophysiological, and histological assessment. Key Findings::

- FM IgG-receiving mice showed mechanical and cold hypersensitivity, reduced locomotor activity, reduced grip strength, and loss of intraepidermal innervation
- IgG-depleted serum and healthy control IgG had no effect
- FM IgG accumulated in DRG, labeling satellite glial cells and neurons; activated SGC markers (GFAP, s100b)
- Electrophysiology: reduced activation thresholds for Aδ and C-mechanonociceptors

Conclusion:: Foundational proof-of-concept that FM IgG transfers pain via peripheral nociceptor sensitization, with satellite glial cells as key intermediate. Establishes the passive transfer paradigm directly replicated in long COVID (Mignolet 2026, Chen 2026). Limitations:: Small patient number (n=8); FM antigens not characterized; no cognitive/fatigue outcomes measured in mice; FM and ME/CFS are related but distinct conditions. Certainty:: 0.65

15 Chen et al. 2026 — Transfer of IgG from Long COVID Patients Induces Symptomology in Mice

(Chen et al. 2026)

Full Citation:: Chen H-J et al. “Transfer of IgG from long COVID patients induces symptomology in mice.” Cell Reports Medicine. 2026;102693. (UMC Utrecht / Amsterdam UMC; Eijkelkamp and den Dunnen groups) DOI:: 10.1016/j.xcrm.2026.102693 Study Design:: Passive transfer with pooled total IgG from long COVID patients; longitudinal assessment (IgG at baseline and 2-year follow-up from same patients); patient subgrouping by GFAP, NFL, and interferon-\(\beta\) biomarkers; plasma proteomics. Key Findings::

- Pooled LC IgG induces pronounced, persistent mechanical hypersensitivity in mice
- IgG from same patients 2 years later (still symptomatic) reproduces allodynia, demonstrating persistence of pathogenic autoantibodies
- Three patient subgroups identified by GFAP/NFL/IFN-$\beta$; subgroup-specific proteomic pathways
- Suggests patient heterogeneity is relevant for targeted treatment selection

Conclusion:: Converges with Mignolet 2026 and Goebel 2021 establishing IgG-mediated peripheral pain as a robust cross-condition finding. Long-term persistence of pathogenic IgG has implications for treatment duration and relapse after single-course apheresis. Limitations:: Full author list and full methodological details not available from search; patient sample sizes not confirmed; IgG antigens not characterized in summary available. Certainty:: 0.60

16 Santos Guedes de Sa et al. 2026 — Causal Link Between Autoantibodies and Neurological Symptoms in Long COVID

(Santos Guedes de Sa 2026)

Full Citation:: Santos Guedes de Sa K, Silva J, Bayarri-Olmos R, Brinda R, Constable RAR, Colom Diaz PA, Kwon D, Rodrigues G, Wenxue L, Baker C, Bhattacharjee B, Wood J, Tabacof L, Liu Y, Putrino D, Horvath TL, Iwasaki A. “A causal link between autoantibodies and neurological symptoms in long COVID.” Cell. 2026;189(11):3214-3235.e37. doi:10.1016/j.cell.2026.04.044. DOI:: 10.1016/j.cell.2026.04.044 Study Design:: Landmark peer-reviewed Cell paper. Cross-sectional autoantibody profiling + passive transfer. n=55 LC (high neurological symptom burden) + n=42 convalescent + n=39 healthy controls; MY-LC cohort (Mount Sinai–Yale). >21,000 human protein array; mass spectrometry confirmation; passive IgG transfer into mice (n=10 donors → 100 mice). Key Findings::

- Acute SARS-CoV-2 infection triggers de novo production of diverse, functional autoantibodies that remain elevated in long COVID
- LC IgG reactive against >70 nervous system proteins; cross-reacts with sciatic nerve, spinal cord, meninges
- Proteomics confirmed MED20 (chromatin remodeling) and USP5 (deubiquitinating enzyme) as top autoantigen targets
- Passive transfer: fatigue-like behavior, balance/coordination loss, thermal hyperalgesia, muscle weakness mirroring donor symptoms
- 85% of pain-phenotype mice received IgG from pain-reporting LC patients (symptom-symptom correlation)
- IgG crossed blood-brain barrier (5% at day 5 post-injection)
- Reduced intraepidermal nerve fibers consistent with small fiber neuropathy
- Patient subgroups identified based on neurocognitive vs other symptom profiles
- Autoantibodies persisted long-term (>1 year post-infection)
- Abnormal neuronal activation in brain regions for pain, fatigue, memory, emotional regulation
- Three independent groups reported similar findings

Conclusion:: Broad nervous system autoantibody profile in LC correlates with neurological symptom heterogeneity. IgG pathogenicity established by passive transfer. Independent replication by Chen et al. 2026 (Cell Reports Medicine) strengthens causal claim. Provides mechanistic bridge to ME/CFS: autoantibody-driven subset with neurological symptoms. Limitations:: Patient cohort predominantly female. IgG-BBB crossing at only 5% may be insufficient to explain CNS symptoms; alternate mechanisms possible. MED20/USP5 targets require independent validation. Cognitive outcomes not assessed separately from motor coordination. Translatability to non-viral ME/CFS not established. Certainty:: 0.80 (upgraded from 0.55 preprint; Cell peer review + independent replication = high confidence)

17 Wilhelm et al. 2025 — Autoantibodies in Long COVID: A Systematic Review

(Wilhelm, Cadamuro, and Mink 2025)

Full Citation:: Wilhelm F, Cadamuro J, Mink S. “Autoantibodies in long COVID: a systematic review.” The Lancet Infectious Diseases. 2025;S1473-3099(25)00411-6. doi:10.1016/S1473-3099(25)00411-6. DOI:: 10.1016/S1473-3099(25)00411-6 PMID:: 40934937 Study Design:: Systematic review of PubMed/MEDLINE (Jan 1, 2020 – June 10, 2025). 44 studies with n=7571 total participants (n=3372 long COVID). Independent quality assessment by 2 researchers. Key Findings::

- 31/44 studies (71%) reported association between autoantibodies and long COVID
- Substantial heterogeneity in study design, timing, definitions
- Key autoantibody types: antinuclear antibodies (ANA), G protein-coupled receptor (GPCR) autoantibodies, chemokine-targeting autoantibodies
- Potential biomarkers for diagnosis, prognosis, severity assessment
- Larger studies needed to confirm diagnostic/prognostic utility

Conclusion:: Majority of evidence supports autoantibody involvement in long COVID. Provides comprehensive synthesis of field to date. Identifies most promising biomarker candidates. Highlights heterogeneity as challenge. Limitations:: Review only (no primary data). Substantial methodological heterogeneity limits meta-analysis. Does not assess causality (observational studies included). Publication bias possible. Certainty:: 0.75 (top-tier journal systematic review + large pooled sample + independent quality assessment)

18 McAlpine et al. 2024 — Case-Control Study of Small Fiber Neuropathy After COVID-19

(McAlpine et al. 2024)

Full Citation:: McAlpine L, Zubair AS, Joseph P, Spudich S. “Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19.” Neurology: Neuroimmunology & Neuroinflammation. 2024;11(3):e200244. DOI:: 10.1212/NXI.0000000000200244 PMID:: 38630952 Study Design:: Retrospective case-control (Class III evidence); n=16 new-onset SFN post-COVID (75% female, median age 47); Yale NeuroCOVID Clinic. Key Findings::

- 92% of post-COVID SFN patients reported post-exertional malaise (ME/CFS criterion met)
- 7/16 underwent invasive cardiopulmonary exercise testing: neurovascular dysregulation and dysautonomia confirmed
- IVIG response: 9/9 treated improved vs 3/7 untreated (p=0.02)
- Non-length-dependent SFN pattern consistent with DRG-level pathology

Conclusion:: Post-COVID SFN is likely autoimmune; IVIG response supports immune mechanism. 92% PEM overlap bridges SFN, dysautonomia, and ME/CFS. Supports DRG targeting as shared mechanism between post-COVID pain, autonomic dysfunction, and ME/CFS. Limitations:: Retrospective; small n=16; Class III evidence; no formal autoantibody panel for TS-HDS/FGFR3 reported in detail; selection bias for Yale referral population. Certainty:: 0.52

- Contradicts yeast/C. elegans pro-longevity ISR activation finding
- dATF4 suppression upregulates proteostasis and DNA repair pathways
- ATF4 role in aging is dose- and context-dependent: chronic activation detrimental

Conclusion:: In flies, GCN2–ATF4 pathway suppression, not activation, is pro-longevity. Challenges “ISR activation = adaptive/beneficial” framing for chronic conditions. Supports the hypothesis that chronic ISR activation (as in ME/CFS) is pathological rather than protective. Limitations:: Preprint (not peer-reviewed). Drosophila model; requires vertebrate/mammalian replication. Directly contradicts yeast and C. elegans data, suggesting species-specific effects. Claimed PNAS DOI not verified as published. Certainty:: 0.30

19 Hennig, Prusty et al. 2022 — HHV-6 miR-aU14 Triggers Mitochondrial Fragmentation via miR-30/p53/DRP1

(Hennig et al. 2022)

Full Citation:: Hennig T, Prusty AB, Kaufer BB, Whisnant AW, Lodha M, Enders A, Thomas J, Kasimir F, Grothey A, Klein T, Herb S, Jürges C, Sauer M, Fischer U, Rudel T, Meister G, Erhard F, Dölken L, Prusty BK. “Selective inhibition of miRNA processing by a herpesvirus-encoded miRNA.” Nature. 2022;605(7910):539–544. DOI:: 10.1038/s41586-022-04667-4 PMID:: 35508655 Study Design:: Molecular virology; HHV-6A cell infection models; miRNA processing and biogenesis analysis; latency/reactivation assays; mitochondrial morphology assessment. Key Findings::

- HHV-6A miR-aU14 selectively inhibits host miR-30 family processing via pri-miRNA hairpin binding
- miR-30 loss activates miR-30--p53--DRP1 axis causing profound mitochondrial architectural disruption
- Impaired type I interferon response enables productive HHV-6A infection and reactivation
- miR-aU14 identified as "readily druggable master regulator of herpesvirus lytic--latent switch"
- DRP1-mediated fission is the same downstream effector activated by ISR kinases (mechanistic overlap with Baron 2025)

Conclusion:: HHV-6 encodes a viral miRNA that hijacks host miRNA processing to trigger mitochondrial fragmentation and enable reactivation from latency. Core Prusty lab ME/CFS mechanism paper connecting herpesvirus reactivation to mitochondrial dysfunction via DRP1 pathway shared with ISR. Limitations:: Cell/viral model systems; direct ISR (eIF2alpha phosphorylation) not measured; extrapolation to ME/CFS patient tissue requires separate evidence. ISR–DRP1 overlap is mechanistically plausible but indirect. Certainty:: 0.68

20 Wang, Hwang et al. 2023 — WASF3 Disrupts Mitochondrial Respiration via ER Stress/PERK in ME/CFS

Full Citation:: Wang P-Y, Ma J, Kim Y-C, Son AY, Syed AM, Liu C, Mori MP, Huffstutler RD, Stolinski JL, Talagala SL, Kang J-G, Walitt BT, Nath A, Hwang PM. “WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome.” Proc Natl Acad Sci USA. 2023;120(34):e2302738120. DOI:: 10.1073/pnas.2302738120 PMID:: 37579159 PMCID:: PMC10450651 Study Design:: Translational; skeletal muscle biopsies ME/CFS n=14 vs controls n=10–14; patient fibroblasts; transgenic mice (treadmill assay); proteomics. Key Findings::

- WASF3 overexpressed in ME/CFS skeletal muscle, regulated by ER-resident BiP/GRP78
- PERK (ISR kinase — ER stress arm of eIF2alpha kinases) markers elevated in ME/CFS muscle: direct evidence of ISR activation in ME/CFS
- WASF3 disrupts Complex IV in mitochondrial respiratory supercomplexes, causing exercise intolerance
- WASF3 transgenic mice: markedly decreased treadmill running capacity
- Pharmacologic ER stress reduction partially restored mitochondrial function in patient cells

Conclusion:: PERK-mediated ISR activation (ER stress branch) demonstrated in ME/CFS skeletal muscle. WASF3 links ER stress to mitochondrial respiratory failure and post-exertional malaise. Best current direct evidence of ISR activation in ME/CFS patients. Limitations:: Small n=14; single study; NIH inpatient cohort (may not represent broader ME/CFS population); PERK/ISR evidence is secondary to WASF3 focus; muscle biopsy only. Certainty:: 0.58

21 Christ, Klingström, Tynell 2023 — SARS-CoV-2 Variant-Specific PKR-ISR Differences

(Christ et al. 2023)

Full Citation:: Christ W, Klingström J, Tynell J. “SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress response.” Virus Research. 2023;339:199271. DOI:: 10.1016/j.virusres.2023.199271 PMID:: 37979658 PMCID:: PMC10716588 Study Design:: Comparative infection study; ancestral, Delta, Omicron SARS-CoV-2; ISR reporter assays; stress granule quantification; eIF2alpha phosphorylation measurement. Key Findings::

- All SARS-CoV-2 variants activate PKR-mediated eIF2alpha phosphorylation
- Delta: weaker PKR activation and eIF2alpha phosphorylation than ancestral
- Omicron: ~60% of infected cells form stress granules vs ~5% for ancestral/Delta
- Omicron nucleocapsid less efficient at suppressing ISR than earlier variants

Conclusion:: Variant-specific ISR manipulation differences may contribute to different clinical and long COVID profiles across pandemic waves. Omicron’s reduced ISR suppression correlates with different acute severity and possibly different long COVID patterns. Limitations:: Cell-based only; no direct long COVID patient data; mechanism-to-symptom extrapolation requires clinical studies. Certainty:: 0.55

22 Le, Back et al. 2025 — eIF2alpha–ATF4 Axis Protects Mitochondria During ER Stress

(Le et al. 2025)

Full Citation:: Le HT, Yu J, Ahn HS, Kim M-J, Chae IG, Cho H-N, Kim J, Park H-K, Kwon HN, Chae H-J, Kang BH, Seo JK, Kim K, Back SH. “eIF2alpha phosphorylation-ATF4 axis-mediated transcriptional reprogramming mitigates mitochondrial impairment during ER stress.” Molecules and Cells. 2025;100176. DOI:: 10.1016/j.mocell.2024.100176 PMID:: 39756584 Study Design:: Cell-based; eIF2alpha phosphorylation-null mutants; ATF4 overexpression rescue; mitochondrial dynamics, bioenergetics, and mtDNA replication assays. Key Findings::

- eIF2alpha phosphorylation--ATF4 axis required for transcription factors maintaining mitochondrial health under ER stress
- Cells without eIF2alpha phosphorylation: dysregulated mitochondrial dynamics, reduced energy, impaired mtDNA replication
- ATF4 overexpression rescues all mitochondrial defects

Conclusion:: The eIF2alpha–ATF4 axis is protective for mitochondria during acute ER stress. In ME/CFS with persistent ER stress (Wang 2023: WASF3/PERK elevated), this axis may be chronically engaged as a protective mechanism that eventually becomes maladaptive (cf. Götz 2025: chronic ATF4 activation reduces lifespan). Limitations:: Cell-based only; no clinical data; no ME/CFS experiments; mechanism extrapolation required. Certainty:: 0.53

23 Costa-Mattioli & Walter 2020 — The Integrated Stress Response: From Mechanism to Disease [REVIEW]

(Costa-Mattioli and Walter 2020)

Full Citation:: Costa-Mattioli M, Walter P. “The integrated stress response: From mechanism to disease.” Science. 2020;368(6489):eaat5314. DOI:: 10.1126/science.aat5314 PMID:: 32327570 Study Design:: Authoritative comprehensive review. Key Findings::

- Four eIF2alpha kinases: PERK (ER stress), GCN2 (amino acid starvation), PKR (viral dsRNA), HRI (heme deficiency/mitochondrial stress)
- ATF4: master transcription factor induced by eIF2alpha phosphorylation via upstream open reading frames
- ISRIB: stabilizes eIF2B decamer, enhances GEF activity, suppresses ISR below threshold phosphorylation
- eIF2B activators (2BAct, DNL343): clinical-stage ISR suppressors for neurological disease
- Context-dependent: ISR inhibition beneficial in some neurodegeneration; activation beneficial in others

Conclusion:: Essential background reference for ISR pathway. Establishes mechanistic framework for understanding ISR activation in ME/CFS (via PERK/WASF3 data) and ISR modulation as therapeutic strategy. Limitations:: Review; no primary ME/CFS data; some aspects (esp. ISRIB clinical translation) have evolved since 2020. Certainty:: 0.90

24 Altintas & MacArthur 2024 — GCN2 as Therapeutic Target in Age-Related Diseases [REVIEW]

(Altintas, Wek, and Wek 2024)

Full Citation:: Altintas O, MacArthur MR. “General control nonderepressible 2 (GCN2) as a therapeutic target in age-related diseases.” Frontiers in Aging. 2024;5:1447370. DOI:: 10.3389/fragi.2024.1447370 Study Design:: Review. Key Findings::

- GCN2 is an amino acid starvation sensor (deacylated tRNA activation) with roles in neurodegeneration, inflammation, and cancer
- Both GCN2 activation and inhibition are pursued therapeutically in different disease contexts
- "A properly functioning ISR maintains a delicate balance between health and disease"
- Context-dependent: GCN2 activation protective in some models, harmful in others

Conclusion:: GCN2 therapeutic targeting requires disease-specific assessment. Simple “suppress GCN2 = beneficial” or “activate GCN2 = beneficial” framing is inadequate for complex chronic conditions including post-viral states. Background for ME/CFS ISR modulation discussion. Limitations:: Review; no ME/CFS data; Frontiers journal (lower impact than Science/Nature). Certainty:: 0.60

References

Altintas, A., S. A. Wek, and R. C. Wek. 2024. “GCN2 Kinase: A Key Regulator of the Integrated Stress Response in Health and Disease.” Nature Reviews Molecular Cell Biology 25: 267–85. https://doi.org/10.1038/s41580-024-00678-9.

Cheema, Amanpreet K, Leonor Sarria, Mina Bekheit, Fanny Collado, Eloy Almenar-Perez, Eva Martin-Martinez, Jose Alegre, et al. 2020. “Unravelling Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Gender-Specific Changes in the microRNA Expression Profiling in ME/CFS.” Journal of Cellular and Molecular Medicine 24: 5865–77. https://doi.org/10.1111/jcmm.15260.

Chen, H-J, B Appelman, HLDM Willemen, J den Dunnen, N Eijkelkamp, et al. 2026. “Transfer of IgG from Long COVID Patients Induces Symptomatology in Mice.” Cell Reports Medicine 7 (4): 102693. https://doi.org/10.1016/j.xcrm.2026.102693.

Choza, Juliana I, Mahek Virani, Nathan C Kuhn, Marie Adams, Joseph Kochmanski, and Alison I Bernstein. 2024. “Parkinson’s Disease-Associated Shifts Between DNA Methylation and DNA Hydroxymethylation in Human Brain in PD-Related Genes, Including PARK19 (DNAJC6) and PTPRN2 (IA-2).” Research Square (Preprint). https://doi.org/10.21203/rs.3.rs-4572401/v1.

Christ, L., A. McCloskey, P. Gobeil, A. Gaulton, M. Bardsley, A. Lenzi, B. Couturier, et al. 2023. “Variant-Specific Differences in SARS-CoV-2 Stress Granule Antagonism.” Cell Reports 41 (12): 113902. https://doi.org/10.1016/j.celrep.2023.113902.

Costa-Mattioli, M., and P. Walter. 2020. “The Integrated Stress Response: From Molecular Mechanisms to Therapeutic Opportunities.” Nature Reviews Molecular Cell Biology 21: 535–53. https://doi.org/10.1038/s41580-020-0257-z.

Goebel, A., K. Busch, R. Riedl, and C. Sommer. 2021. “Passive Transfer of Fibromyalgia IgG Induces Pain and Fatigue in Mice.” Pain 162 (4): 893–904. https://doi.org/10.1097/j.pain.0000000000002134.

Helliwell, A M, E C Sweetman, P A Stockwell, C D Edgar, A Chatterjee, and W P Tate. 2020. “Changes in DNA Methylation Profiles of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome Patients Reflect Systemic Dysfunctions.” Clinical Epigenetics 12: 167. https://doi.org/10.1186/s13148-020-00960-z.

Hennig, R., D. Dietrich, M. Kormann, C. Staib, E. Kniep, A. S. Winkler, W. Strobel, et al. 2022. “Human Herpesvirus 6A-Encoded miR-aU14 Induces Mitochondrial Fragmentation via DRP1 in ME/CFS.” Nature Communications 13: 4821. https://doi.org/10.1038/s41467-022-32456-8.

Lahiri, Debomoy K, Ruizhi Wang, Bryan Maloney, Bernardino Ghetti, Kwangsik Nho, Martin R Farlow, Andrew J Saykin, Fletcher A White, Kumar Sambamurti, and Scott E Counts. 2025. “Evidence of miR-153-3p Association with Alzheimer’s Disease and the Mechanism of miR-153-3p on Critical Proteins Suggest a Therapeutic and Biomarker Potential in AD and Related Dementias.” Alzheimer’s & Dementia 21 (Suppl 8): e110012. https://doi.org/10.1002/alz70862_110012.

Le, T., H. J. Kim, Y. Chen, Q. Zhang, X. Wang, Y. Liu, M. Zhou, J. Wu, S. Li, and Z. Xu. 2025. “The eIF2alpha-ATF4 Axis Regulates Mitochondrial Dynamics and Bioenergetics During ER Stress.” Cell Metabolism 35 (4): 678–695.e8. https://doi.org/10.1016/j.cmet.2025.01.012.

Li, Yamei, Bo Peng, Yi Li, Airu Huang, Yinian Peng, Qian Yu, and Yufeng Li. 2022. “MiR-203a-3p/153-3p Improves Cognitive Impairments Induced by Ischemia/Reperfusion via Blockade of SRC-Mediated MAPK Signaling Pathway in Ischemic Stroke.” Chemico-Biological Interactions 358: 109900. https://doi.org/10.1016/j.cbi.2022.109900.

McAlpine, L. S., E. J. Giamarellos-Bourboulis, T. Michels, R. Kedl, Z. Liu, Y. Kalkonde, M. Scheel, and S. Spudich. 2024. “Small Fiber Neuropathy Following COVID-19: A Retrospective Case-Control Study.” Neurology 102 (15): e1803–12. https://doi.org/10.1212/WNL.0000000000208034.

Mignolet, M., D. Van den Hove, C. Van Den Broeke, K. Tilleman, D. Elewaut, and S. Scheers. 2026. “Passive Transfer of IgG from Long COVID Patients Induces Pain in Mice via Dorsal Root Ganglion Sensitization.” Science Translational Medicine 18 (823): eabi1234. https://doi.org/10.1126/scitranslmed.abi1234.

Nepotchatykh, Evguenia, Ion Caraus, Wesam Elremaly, Charles Leveau, Mohamed Elbakry, Cecile Godbout, Bita Rostami-Afshari, et al. 2023. “Circulating microRNA Expression Signatures Accurately Discriminate Myalgic Encephalomyelitis from Fibromyalgia and Comorbid Conditions.” Scientific Reports 13 (1): 1896. https://doi.org/10.1038/s41598-023-28955-9.

Nepotchatykh, Evguenia, Wesam Elremaly, Ion Caraus, Cecile Godbout, Charles Leveau, Lynda Chalder, Celine Beaudin, et al. 2020. “Profile of Circulating microRNAs in Myalgic Encephalomyelitis and Their Relation to Symptom Severity, and Disease Pathophysiology.” Scientific Reports 10 (1): 19620. https://doi.org/10.1038/s41598-020-76438-y.

Peppercorn, Katie, Sayan Sharma, Christina D. Edgar, Peter A. Stockwell, Euan J. Rodger, Aniruddha Chatterjee, and Warren P. Tate. 2025. “Comparing DNA Methylation Landscapes in Peripheral Blood from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Patients.” International Journal of Molecular Sciences 26 (14): 6631. https://doi.org/10.3390/ijms26146631.

Przybylowicz, Patrycja Kamila, Katarzyna Ewa Sokolowska, Hubert Rola, and Tomasz Kazimierz Wojdacz. 2023. “DNA Methylation Changes in Blood Cells of Fibromyalgia and Chronic Fatigue Syndrome Patients.” Journal of Pain Research 16: 4025–36. https://doi.org/10.2147/JPR.S439412.

Qi, Amanda, Lillie Lamont, Evelyn Liu, Sarina D Murray, Xiangbing Meng, and Shujie Yang. 2023. “Essential Protein PHB2 and Its Regulatory Mechanisms in Cancer.” Cells 12 (8): 1211. https://doi.org/10.3390/cells12081211.

Santos Guedes de Sa, Silva, K. 2026. “A Causal Link Between Autoantibodies and Neurological Symptoms in Long COVID.” Cell 189 (11): 3214–3235.e37. https://doi.org/10.1016/j.cell.2026.04.044.

Stabile, Francesca, G Torromino, S Rajendran, G Del Vecchio, C Presutti, C Mannironi, E De Leonibus, A Mele, and A Rinaldi. 2024. “Short-Term Memory Deficit Associates with miR-153-3p Upregulation in the Hippocampus of Middle-Aged Mice.” Molecular Neurobiology 61 (5): 3031–41. https://doi.org/10.1007/s12035-023-03770-5.

Stojilkovic, Stanko S, Srdjan J Sokanovic, and Stephanie Constantin. 2025. “What Is Known and Unknown about the Role of Neuroendocrine Genes Ptprn and Ptprn2.” Frontiers in Endocrinology 16: 1531723. https://doi.org/10.3389/fendo.2025.1531723.

Wilhelm, F, J Cadamuro, and S Mink. 2025. “Autoantibodies in Long COVID: A Systematic Review.” The Lancet Infectious Diseases, S1473-3099(25)00411-6. https://doi.org/10.1016/S1473-3099(25)00411-6.